Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta-1b: latest published results, 1995

J H Noseworthy1

  • 1Department of Neurology, Mayo Clinic/Mayo Foundation, Rochester, Minnesota 55905, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disability as an outcome in MS clinical trials.

Neurology·2008
Same author

A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.

Neurology·2005
Same author

Disability profile of MS did not change over 10 years in a population-based prevalence cohort.

Neurology·2004
Same author

Change in MS-related disability in a population-based cohort: a 10-year follow-up study.

Neurology·2004
Same author

Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000.

Neurology·2003
Same author

International consensus statement on the use of disease-modifying agents in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2002
Same journal

Association of epiretinal membranes with disability in people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Epiretinal membranes in multiple sclerosis: A window into glial pathobiology?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Interferon beta-Ib (Betaseron) effectively treats relapsing-remitting MS by reducing relapses and MRI progression. However, neutralizing antibodies can diminish its clinical effectiveness over time.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Pharmacology

Background:

  • Relapsing-remitting multiple sclerosis (MS) is a chronic autoimmune disease.
  • Interferon beta-Ib (Betaseron) is a therapeutic agent used for MS treatment.
  • Previous studies indicated Betaseron's efficacy in reducing MS disease activity.

Purpose of the Study:

  • To review new findings on the treatment effects of Interferon beta-Ib (Betaseron) in relapsing-remitting MS.
  • To highlight the impact of neutralizing antibody formation on Betaseron's clinical effectiveness.
  • To discuss the relationship between MRI-detected disease activity and clinical outcomes.

Main Methods:

  • Review of data from a randomized, double-blind, placebo-controlled study of Betaseron.
  • Analysis of findings from the Betaseron extension trial and National Institutes of Health studies.

Related Experiment Videos

  • Evaluation of neutralizing antibody formation in patients treated with Betaseron.

    • Main Results:

    • Interferon beta-Ib (Betaseron) reduced relapse rates, severity, and MRI progression in relapsing-remitting MS patients.
    • Neutralizing antibodies developed in 38% of patients on high-dose Betaseron at 3 years, correlating with loss of clinical efficacy.
    • MRI was an imperfect predictor of clinical disease activity; low-dose Betaseron patients showed earlier 'confirmed treatment failure' than placebo despite MRI benefits.

    Conclusions:

    • Interferon beta-Ib (Betaseron) demonstrates significant benefits in managing relapsing-remitting MS.
    • The development of neutralizing antibodies is a critical factor that can limit Betaseron's long-term clinical effectiveness.
    • Careful consideration of potential antibody formation is necessary when initiating Betaseron therapy, and MRI findings should be interpreted alongside clinical status.